Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Over one year, liraglutide did not significantly improve the primary endpoint (change in cerebral glucose metabolic rate in certain brain regions), but secondary endpointsincluding brain volume loss, and cognitive measuresshowed benefit: ~50% less loss in several brain regions compared to placebo
5 These guidelines align with the American Diabetes Association (ADA) standards of care which also provide strong recommendations based on robust clinical trial data supporting the cardiovascular benefits of GLP-1 RAs, particularly in patients with established cardiovascular disease and chronic kidney disease (CKD)
Your Body's Response: We monitor how you feel every step of the way, because your feedback is a critical part of the journey
,
